Search Results - "PABINGER, I."

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants by Ay, C., Beyer-Westendorf, J., Pabinger, I.

“…Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications—including bleeding and potential drug–drug…”
Get full text

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline by Falanga, A., Ay, C., Di Nisio, M., Gerotziafas, G., Jara-Palomares, L., Langer, F., Lecumberri, R., Mandala, M., Maraveyas, A., Pabinger, I., Sinn, M., Syrigos, K., Young, A., Jordan, K.

“…•Cancer-associated thrombosis is a major health problem that affects morbidity and mortality of people with cancer.•Surgical and systemic pharmacological…”
Get full text

Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients by Mauracher, L.‐M., Posch, F., Martinod, K., Grilz, E., Däullary, T., Hell, L., Brostjan, C., Zielinski, C., Ay, C., Wagner, D. D., Pabinger, I., Thaler, J.

“…Essentials Neutrophil extracellular traps (NETs) might play a role in cancer‐related coagulopathy. We determined NET biomarkers and followed cancer patients…”
Get full text

Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients by THALER, J., AY, C., MACKMAN, N., BERTINA, R. M., KAIDER, A., MAROSI, C., KEY, N. S., BARCEL, D. A., SCHEITHAUER, W., KORNEK, G., ZIELINSKI, C., PABINGER, I.

“…Background:  Tissue factor (TF) expression by tumors contributes to tumor growth. Release of TF‐positive microparticles (MPs) may contribute to venous…”
Get full text

Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial by PABINGER, I., BRENNER, B., KALINA, U., KNAUB, S., NAGY, A., OSTERMANN, H.

“…Background: Prothrombin complex concentrate (PCC) can substantially shorten the time needed to reverse antivitamin K oral anticoagulant therapy (OAT)…”
Get full text

Platelets in cancer and thrombosis by Riedl, J, Pabinger, I, Ay, C

“…Platelets are the smallest circulating blood cells and their major function is the maintenance of haemostasis. They do not have a nucleus, but instead a…”
Get more information

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism by Mir Seyed Nazari, P., Riedl, J., Preusser, M., Posch, F., Thaler, J., Marosi, C., Birner, P., Ricken, G., Hainfellner, J. A., Pabinger, I., Ay, C.

“…Essentials Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin…”
Get full text

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study by Francis, C. W., Kessler, C. M., Goldhaber, S. Z., Kovacs, M. J., Monreal, M., Huisman, M. V., Bergqvist, D., Turpie, A. G., Ortel, T. L., Spyropoulos, A. C., Pabinger, I., Kakkar, A. K.

“…Summary Background Treatment of venous thromboembolism (VTE) in patients with cancer has a high rate of recurrence and bleeding complications. Guidelines…”
Get full text

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII by Reding, M. T., Ng, H. J., Poulsen, L. H., Eyster, M. E., Pabinger, I., Shin, H.‐J., Walsch, R., Lederman, M., Wang, M., Hardtke, M., Michaels, L. A.

“…Essentials Recombinant factor VIII BAY 94‐9027 conjugates in a site‐specific manner with polyethylene glycol. BAY 94‐9027 was given to patients with severe…”
Get full text

The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study by DE LAAT, B., PENGO, V., PABINGER, I., MUSIAL, J., VOSKUYL, A. E., BULTINK, I. E. M., RUFFATTI, A., ROZMAN, B., KVEDER, T., DE MOERLOOSE, P., BOEHLEN, F., RAND, J., ULCOVA‐GALLOVA, Z., MERTENS, K., DE GROOT, P. G.

“…Background: Diagnosis of the antiphospholipid syndrome (APS) is difficult as a result of limited specificity of existing assays for detecting clinically…”
Get full text

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer by FARGE, D., DEBOURDEAU, P., BECKERS, M., BAGLIN, C., BAUERSACHS, R. M., BRENNER, B., BRILHANTE, D., FALANGA, A., GEROTZAFIAS, G. T., HAIM, N., KAKKAR, A. K., KHORANA, A. A., LECUMBERRI, R., MANDALA, M., MARTY, M., MONREAL, M., MOUSA, S. A., NOBLE, S., PABINGER, I., PRANDONI, P., PRINS, M. H., QARI, M. H., STREIFF, M. B., SYRIGOS, K., BOUNAMEAUX, H., BÜLLER, H. R.

“…Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been…”
Get full text

Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment by Reitter, E.‐M., Kaider, A., Ay, C., Quehenberger, P., Marosi, C., Zielinski, C., Pabinger, I.

“…Essentials Hemostasis biomarkers impact thrombosis occurrence and survival in cancer patients. We performed a longitudinal analysis of hemostatic parameters in…”
Get full text

Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality by Ay, C., Posch, F., Kaider, A., Zielinski, C., Pabinger, I.

“…Summary Background In studies on cancer‐associated venous thromboembolism (VTE), patients not only are at risk for VTE but also may die from their underlying…”
Get full text

Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates by Mackensen, S., Kalnins, W., Krucker, J., Weiss, J., Miesbach, W., Albisetti, M., Pabinger, I., Oldenburg, J.

“…Introduction National Member Organisations (NMO) of persons with haemophilia (PWH) from the DACH Region (D = Germany, A = Austria, CH = Switzerland) were…”
Get full text

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma by GORCZYCA, M. E., NAIR, S. C., JILMA, B., PRIYA, S., MALE, C., REITTER, S., KNOEBL, P., GILBERT, J. C., SCHAUB, R. G., Dockal, M., McGINNESS, K. E., PABINGER, I., SRIVASTAVA, A.

“…Background:  Tissue factor pathway inhibitor (TFPI) is the major inhibitor of tissue factor‐initiated coagulation, making it an interesting and novel…”
Get full text

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer by DEBOURDEAU, P., FARGE, D., BECKERS, M., BAGLIN, C., BAUERSACHS, R. M., BRENNER, B., BRILHANTE, D., FALANGA, A., GEROTZAFIAS, G. T., HAIM, N., KAKKAR, A. K., KHORANA, A. A., LECUMBERRI, R., MANDALA, M., MARTY, M., MONREAL, M., MOUSA, S. A., NOBLE, S., PABINGER, I., PRANDONI, P., PRINS, M. H., QARI, M. H., STREIFF, M. B., SYRIGOS, K., BÜLLER, H. R., BOUNAMEAUX, H.

“…Background: Although long‐term indwelling central venous catheters (CVCs) may lead to pulmonary embolism (PE) and loss of the CVC, there is lack of consensus…”
Get full text

Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) by Pabinger, I., Ay, C., Dunkler, D., Thaler, J., Reitter, E.‐M., Marosi, C., Zielinski, C., Mannhalter, C.

“…Summary Background Patients with cancer are at an increased risk for venous thromboembolism (VTE). The risk varies markedly in different patient populations…”
Get full text

High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) by SIMANEK, R., VORMITTAG, R., AY, C., ALGUEL, G., DUNKLER, D., SCHWARZINGER, I., STEGER, G., JAEGER, U., ZIELINSKI, C., PABINGER, I.

“…Background: In cancer patients, laboratory parameters that predict venous thromboembolism (VTE) are scarce. Increased platelet count has been found to be a…”
Get full text

High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients: The Cancer and Thrombosis Study by Vormittag, R, Simanek, R, Ay, C, Dunkler, D, Quehenberger, P, Marosi, C, Zielinski, C, Pabinger, I

“…OBJECTIVE—Patients with cancer are at an increased risk for venous thromboembolism (VTE). Clotting factor VIII activity (FVIII) has been established as risk…”
Get full text

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB) by Gebhart, J., Hofer, S., Panzer, S., Quehenberger, P., Sunder‐Plassmann, R., Hoermann, G., Eigenbauer, E., Haslacher, H., Kepa, S., Kyrle, P. A., Eichinger, S., Knöbl, P., Eischer, L., Mannhalter, C., Ay, C., Pabinger, I.

“…Introduction Data on clinical characteristics and the prevalence of underlying coagulopathies in patients with mild‐to‐moderate bleeding disorders (MBDs) are…”
Get full text